HKHoe Suk Kim

Hoe Suk Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hoe Suk Kim has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Tables and Figures from Triple-Negative Breast Cancer-Derived Extracellular Vesicles Promote a Hepatic Premetastatic Niche via a Cascade of Microenvironment Remodeling

    by Woohang Heo, Woochan Lee, Jong Ho Cheun, Eun-Shin Lee, Songbin Li, Hoe Suk Kim, Hye-Youn Son, Ju Hee Kim, Yeon Duk Woo, Doo Hyun Chung, et al.

    Supplementary Table 1. Information about patients derived xenograft models and derived patient.Supplementary Table 2. Ontology of differentially expressed genes in metastasis-harboring liver of PDX models.Supplementary Table 3. Differentially expressed genes in liver and lung of metastasis-harboring PDX models.Supplementary Table 4. Human ratio in lung and liver of additional PDX models identified by RNA sequencing.Supplementary Table 5. Gene ontology of co-expressed genes with Cx3cr1 in liver of PDX models identified by RNA sequencing.Supplementary Table 6. Top ranked genes having significant correlation with Cx3cr1 in liver of PDX models identified by RNA sequencing.Supplementary Table 7. Demographic and clinical characteristics of all patients.Supplementary Table 8. Information about used primer sequences for quantitative real-time PCRSupplementary Figure 1. Liver and lung H&E staining pictures of eight nonmetastatic PDX models a. Microscopic images of non-metastasis harboring PDX mouse model's liver (left) and lung (right) taken at 400x magnification.Supplementary Figure 2. Immunohistochemistry about CX3CR1 in liver and lung of breast cancer metastasis patients.Supplementary Figure 3. Hepatic metastasis after four weeks after orthotopic injection of 4T1 breast cancer cells identified by H&E staining.Supplementary Figure 4. Identification of pre-metastatic niche in liver tissues of 4T1 bearing mice a. mRNA expression of inflammation associated genes identified by real-time PCR in liver tissues of 4T1 bearing mice.Supplementary Figure 5. Identification of CX3CR1 positive cell population.Supplementary Figure 6. FACS analysis with anti-CX3CR1 of Raw264.7 macrophage cell lines.Supplementary Figure 7. Trans-well migration assay of BMDM with or without CX3CL1.Supplementary Figure 8. Mmp9 mRNA expression having significant correlation with Cx3cr1 mRNA expression in liver of PDX models.Supplementary Figure 9. MMP9 expression of macrophages with CX3CL1 treatment.Supplementary Figure 10. Signaling pathway of CX3CL1 treated macrophages.Supplementary Figure 11. Splenic injection of 4T1 cells inducing hepatic metastasis within two weeks in most cases.Supplementary Figure 12. mRNA expression about Cx3cr1 and Mmp9 in liver of vehicle or AZD8797 treated BALB/C mice identified by real-time PCR.Supplementary Figure 13. Correlation plot of Tnfa and Cx3cr1 mRNA expression in liver and lung of PDX models.Supplementary Figure 14. EVs isolation of CD63-mRuby-4T1.

  • Open Access

    Data from Triple-Negative Breast Cancer-Derived Extracellular Vesicles Promote a Hepatic Premetastatic Niche via a Cascade of Microenvironment Remodeling

    by Woohang Heo, Woochan Lee, Jong Ho Cheun, Eun-Shin Lee, Songbin Li, Hoe Suk Kim, Hye-Youn Son, Ju Hee Kim, Yeon Duk Woo, Doo Hyun Chung, et al.

    Patients with triple-negative breast cancer (TNBC) often develop metastases in visceral organs including the liver, but the detailed molecular mechanisms of TNBC liver metastasis is not clearly understood. In this study, we tried to dissect the process of premetastatic niche formation in the liver by using patient-derived xenograft (PDX) models of TNBC with different metastatic propensity. RNA sequencing of TNBC PDX models that successfully metastasized to liver showed upregulation of the Cx3cr1 gene in the liver microenvironment. In syngeneic breast cancer models, the Cx3cr1 upregulation in liver preceded the development of cancer cell metastasis and was the result of recruitment of CX3CR1-expressing macrophages. The recruitment was induced by the CX3CL1 production from the liver endothelial cells and this CX3CL1–CX3CR1 signaling in the premetastatic niche resulted in upregulation of MMP9 that promoted macrophage migration and cancer cell invasion. In addition, our data suggest that the extracellular vesicles derived from the breast cancer cells induced the TNFα expression in liver, which leads to the CX3CL1 upregulation. Lastly, the plasma CX3CL1 levels in 155 patients with breast cancer were significantly associated with development of liver metastasis.Implications:Our data provides previously unknown cascades regarding the molecular education of premetastatic niche in liver for TNBC.

  • Open Access

    Anti-cancer drug sensitivity testing and preclinical evaluation of the anti-cancer potential of WEE1 inhibitor in triple-negative breast cancer patient-derived organoids and xenograft models

    by Seungyeon Ryu, Hoe Suk Kim, Sangeun Lee, So-Hyun Yoon, Moonjou Baek, A Young Park, Han-Byoel Lee, Ga Yeon Kim, Kyung Hyeun Park, Ji-Jung Jung, et al.

    Background: Relevant surrogates that maintain the pathological and physiological properties of patient tumors are essential for guiding triple-negative breast cancer (TNBC) therapy. The goals are to generate patient-derived organoids (PDOs), xenografts (PDXs), and PDX-derived organoids (PDXOs), evaluate the therapeutic potential of the WEE1 inhibitor AZD1775, and compare their responses to 18 anti-cancer drugs in PDOs and PDXOs. Methods: PDOs were produced from surgical specimens of patients with TNBC. PDXs were generated by transplanting PDOs into the mammary fat pads of NOD.Cg-Prkdcscid Il2rgtm1wjl/SzJ mice. PDXOs were derived from fresh tumor specimens of PDXs. For drug efficacy, half-maximal inhibitory concentration (IC50) values for 18 anti-cancer drugs on PDOs and PDXOs were calculated using the CellTiter-Glo® 3D cell viability assay in a high-throughput drug screening system. The relationship between WEE1 expression and survival in TNBC-basal-like (BL) patients was analyzed using the Kaplan–Meier Plotter database. Mice were treated with AZD1775 via oral gavage (30 mg/kg). Biological mechanisms underlying the anti-cancer drug responses were evaluated by calcein-AM staining, caspase 3/7 staining, Western blot, flow cytometry, and immunohistochemistry. Results: PDOs were established through subcultures of 2-7 passages. TNBC-BL PDXs expressing CK5, vimentin, and EGFR were generated and expanded over 3-4 generations of transplantation. PDXOs were produced through subcultures of 4-5 passages. PDOs, PDXs, and PDXOs retained the immunohistological characteristics of the relevant patients with TNBC. WEE1 was associated with poor survival outcomes in TNBC-BL patients. The highest cytotoxicity and tumor growth suppression to AZD1775 therapy were observed in PDXOs and PDXs with high WEE1 expression. AZD1775 inhibited WEE1 and CDK1 phosphorylation, increased γH2AX phosphorylation, induced G2/M arrest, and activated caspase 3/7 in PDXOs and PDXs, all associated with DNA damage, mitotic catastrophe, and apoptosis. Anti-cancer drug responses were highly concordant between matched PDOs and PDXOs. The responses of PDOs and PDXOs to anti-cancer drugs were comparable to those of patients receiving neoadjuvant or adjuvant chemotherapy, according to clinical records. Conclusion: PDOs, PDXOs, and PDXs, which maintained the immunological properties of TNBC patient, provide a scientific rationale for future WEE1-targeted clinical trials in TNBC. PDOs and PDXOs represent cost- and time-effective surrogates for predicting prioritized personalized therapy.


  • Open Access

    NSDHL contributes to breast cancer stem-like cell maintenance and tumor-initiating capacity through TGF-β/Smad signaling pathway in MCF-7 tumor spheroid

    by So-Hyun Yoon, Sangeun Lee, Hoe Suk Kim, Junhyuk Song, Moonjou Baek, Seungyeon Ryu, Han-Byoel Lee, Hyeong-Gon Moon, Dong-Young Noh, Sangyong Jon, et al.

    Background: NAD(P)-dependent steroid dehydrogenase-like protein (NSDHL), which is involved in breast tumor growth and metastasis, has been implicated in the maintenance of cancer stem cells. However, its role in regulating breast cancer stem-like cells (BCSCs) remains unclear. We have previously reported the clinical significance of NSDHL in patients with estrogen receptor-positive (ER +) breast cancer. This study aimed to elucidate the molecular mechanisms by which NSDHL regulates the capacity of BCSCs in the ER + human breast cancer cell line, MCF-7. Methods: NSDHL knockdown suppressed tumor spheroid formation in MCF-7 human breast cancer cells grown on ultralow-attachment plates. RNA sequencing revealed that NSDHL knockdown induced widespread transcriptional changes in the MCF-7 spheroids. TGF-β signaling pathway was the most significantly enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway (fold change ≥ 2, P ≤ 0.05) identified in NSDHL-knockdown MCF-7 spheroids compared with the control. In orthotopic tumor models injected with NSDHL-knockdown MCF-7 spheroids, tumor initiation and growth were strongly suppressed compared with those in the control. Results: BCSC populations with CD44+/CD24- and CD49f+/EpCAM + phenotypes and high ALDH activity were decreased in NSDHL-knockdown MCF-7 spheroids and xenograft tumors relative to controls, along with decreased secretion of TGF-β1 and 3, phosphorylation of Smad2/3, and expression of SOX2. In RNA-sequencing data from The (TCGA) database, a positive correlation between the expression of NSDHL and SOX2 was found in luminal-type breast cancer specimens (n = 998). Our findings revealed that NSDHL plays an important role in maintaining the BCSC population and tumor-initiating capacity of ER-positive MCF-7 spheroids, suggesting that NSDHL is an attractive therapeutic target for eliminating BCSCs, thus preventing breast cancer initiation and progression. Conclusions: Our findings suggest that NSDHL regulates the BCSC/tumor-initiating cell population in MCF-7 spheroids and xenograft tumors.


  • Open Access

    Supplementary Tables and Figures from Triple-negative breast cancer-derived extracellular vesicles promote a hepatic pre-metastatic niche via a cascade of microenvironment remodeling

    by Woohang Heo, Woochan Lee, Jong Ho Cheun, Eun-Shin Lee, Songbin Li, Hoe Suk Kim, Hye-Youn Son, Ju Hee Kim, Yeon Duk Woo, Doo Hyun Chung, et al.

    Supplementary Table 1. Information about patients derived xenograft models and derived patient. Supplementary Table 2. Ontology of differentially expressed genes in metastasis-harboring liver of PDX models. Supplementary Table 3. Differentially expressed genes in liver and lung of metastasis-harboring PDX models. Supplementary Table 4. Human ratio in lung and liver of additional PDX models identified by RNA sequencing. Supplementary Table 5. Gene ontology of co-expressed genes with Cx3cr1 in liver of PDX models identified by RNA sequencing. Supplementary Table 6. Top ranked genes having significant correlation with Cx3cr1 in liver of PDX models identified by RNA sequencing. Supplementary Table 7. Demographic and clinical characteristics of all patients. Supplementary Table 8. Information about used primer sequences for quantitative real-time PCR Supplementary Figure 1. Liver and lung H&E staining pictures of eight nonmetastatic PDX models a. Microscopic images of non-metastasis harboring PDX mouse model’s liver (left) and lung (right) taken at 400x magnification. Supplementary Figure 2. Immunohistochemistry about CX3CR1 in liver and lung of breast cancer metastasis patients. Supplementary Figure 3. Hepatic metastasis after four weeks after orthotopic injection of 4T1 breast cancer cells identified by H&E staining. Supplementary Figure 4. Identification of pre-metastatic niche in liver tissues of 4T1 bearing mice a. mRNA expression of inflammation associated genes identified by real-time PCR in liver tissues of 4T1 bearing mice. Supplementary Figure 5. Identification of CX3CR1 positive cell population. Supplementary Figure 6. FACS analysis with anti-CX3CR1 of Raw264.7 macrophage cell lines. Supplementary Figure 7. Trans-well migration assay of BMDM with or without CX3CL1. Supplementary Figure 8. Mmp9 mRNA expression having significant correlation with Cx3cr1 mRNA expression in liver of PDX models. Supplementary Figure 9. MMP9 expression of macrophages with CX3CL1 treatment. Supplementary Figure 10. Signaling pathway of CX3CL1 treated macrophages. Supplementary Figure 11. Splenic injection of 4T1 cells inducing hepatic metastasis within two weeks in most cases. Supplementary Figure 12. mRNA expression about Cx3cr1 and Mmp9 in liver of vehicle or AZD8797 treated BALB/C mice identified by real-time PCR. Supplementary Figure 13. Correlation plot of Tnfa and Cx3cr1 mRNA expression in liver and lung of PDX models. Supplementary Figure 14. EVs isolation of CD63-mRuby-4T1.

  • Open Access

    Data from Triple-negative breast cancer-derived extracellular vesicles promote a hepatic pre-metastatic niche via a cascade of microenvironment remodeling

    by Woohang Heo, Woochan Lee, Jong Ho Cheun, Eun-Shin Lee, Songbin Li, Hoe Suk Kim, Hye-Youn Son, Ju Hee Kim, Yeon Duk Woo, Doo Hyun Chung, et al.

    Triple negative breast cancer (TNBC) patients often develop metastases in visceral organs including the liver but the detailed molecular mechanisms of TNBC liver metastasis is not clearly understood. In this study, we tried to dissect the process of pre-metastatic niche formation in liver by using patient-derived xenograft (PDX) models of TNBC with different metastatic propensity. RNA sequencing of TNBC PDX models that successfully metastasized to liver showed up-regulation of Cx3cr1 gene in the liver microenvironment. In syngeneic breast cancer models, the Cx3cr1 up-regulation in liver preceded the development of cancer cell metastasis and was the results of recruitment of CX3CR1-expressing macrophages. The recruitment was induced by the CX3CL1 production from the liver endothelial cells and this CX3CL1-CX3CR1 signaling in the pre-metastatic niche resulted in up-regulation of MMP9 that promoted macrophage migration and cancer cell invasion. Additionally, our data suggest that the extra-cellular vesicles derived from the breast cancer cells induced the TNF-alpha expression in liver which leads to the CX3CL1 up-regulation. Lastly, the plasma CX3CL1 levels in 155 breast cancer patients were significantly associated with development of liver metastasis. Implications: Our data provides previously unknown cascades regarding the molecular education of pre-metastatic niche in liver for TNBC.

  • Open Access

    Supplementary Tables and Figures from Triple-negative breast cancer-derived extracellular vesicles promote a hepatic pre-metastatic niche via a cascade of microenvironment remodeling

    by Woohang Heo, Woochan Lee, Jong Ho Cheun, Eun-Shin Lee, Songbin Li, Hoe Suk Kim, Hye-Youn Son, Ju Hee Kim, Yeon Duk Woo, Doo Hyun Chung, et al.

    Supplementary Table 1. Information about patients derived xenograft models and derived patient. Supplementary Table 2. Ontology of differentially expressed genes in metastasis-harboring liver of PDX models. Supplementary Table 3. Differentially expressed genes in liver and lung of metastasis-harboring PDX models. Supplementary Table 4. Human ratio in lung and liver of additional PDX models identified by RNA sequencing. Supplementary Table 5. Gene ontology of co-expressed genes with Cx3cr1 in liver of PDX models identified by RNA sequencing. Supplementary Table 6. Top ranked genes having significant correlation with Cx3cr1 in liver of PDX models identified by RNA sequencing. Supplementary Table 7. Demographic and clinical characteristics of all patients. Supplementary Table 8. Information about used primer sequences for quantitative real-time PCR Supplementary Figure 1. Liver and lung H&E staining pictures of eight nonmetastatic PDX models a. Microscopic images of non-metastasis harboring PDX mouse model’s liver (left) and lung (right) taken at 400x magnification. Supplementary Figure 2. Immunohistochemistry about CX3CR1 in liver and lung of breast cancer metastasis patients. Supplementary Figure 3. Hepatic metastasis after four weeks after orthotopic injection of 4T1 breast cancer cells identified by H&E staining. Supplementary Figure 4. Identification of pre-metastatic niche in liver tissues of 4T1 bearing mice a. mRNA expression of inflammation associated genes identified by real-time PCR in liver tissues of 4T1 bearing mice. Supplementary Figure 5. Identification of CX3CR1 positive cell population. Supplementary Figure 6. FACS analysis with anti-CX3CR1 of Raw264.7 macrophage cell lines. Supplementary Figure 7. Trans-well migration assay of BMDM with or without CX3CL1. Supplementary Figure 8. Mmp9 mRNA expression having significant correlation with Cx3cr1 mRNA expression in liver of PDX models. Supplementary Figure 9. MMP9 expression of macrophages with CX3CL1 treatment. Supplementary Figure 10. Signaling pathway of CX3CL1 treated macrophages. Supplementary Figure 11. Splenic injection of 4T1 cells inducing hepatic metastasis within two weeks in most cases. Supplementary Figure 12. mRNA expression about Cx3cr1 and Mmp9 in liver of vehicle or AZD8797 treated BALB/C mice identified by real-time PCR. Supplementary Figure 13. Correlation plot of Tnfa and Cx3cr1 mRNA expression in liver and lung of PDX models. Supplementary Figure 14. EVs isolation of CD63-mRuby-4T1.

  • Open Access

    Impact of media compositions and culture systems on the immunophenotypes of patient-derived breast cancer cells

    by Seungyeon Ryu, So-Hyun Yoon, Junhyuk Song, Yoonjung Choi, Sangeun Lee, Moonjou Baek, Han-Byoel Lee, Sook Young Jeon, Sangyong Jon, Daeyoup Lee, et al.

    Heterogeneous tumor cells are thought to be a significant factor in the failure of endocrine therapy in estrogen receptor-positive (ER+) cancers. Culturing patient-derived breast cancer cells (PDBCCs) provides an invaluable tool in pre-clinical and translational research for the heterogeneity of cancer cells. This study aimed to investigate the effects of different media components and culture methods on the BCSC-associated immunophenotypes and gene expression in ER + PDBCCs. Ten patients with ER + breast cancer were employed in this study, six of whom had neoadjuvant chemotherapy and four of whom did not. PDBCCs were isolated by enzymatic methods using collagen I and hyaluronidase. PDBCCs were grown as monolayers in mediums with different compositions and as multicellular spheroid in a suspended condition. Collagen I-coated plate and ultralow attachment plate coated with polymer-X were used for monolayer and spheroid culture. Flow cytometry, immunofluorescent staining, RT-PCR, and RNA-sequencing were employed to examine the immunophenotype and genetic profile of PDBCCs. More than 95% of PDBCCs sustain EpCAM high/+/fibroblast marker- phenotypes in monolayer conditions by subculturing 3–4 times. A83-01 removal induced senescent cells with high β-galactosidase activity. PDBCCs grown as monolayers were characterized by the majority of cells having an EpCAM+/CD49f + phenotype. Compared to full media in monolayer culture, EGF removal increased EpCAM+/CD49f − phenotype (13.8-fold, p = 0.028), whereas R-spondin removal reduced it (0.8-fold, p = 0.02). A83-01 removal increased EpCAM+/CD24 + phenotype (1.82-fold, p = 0.023) and decreased EpCAM low/-/CD44+/CD24- phenotype (0.45-fold, p = 0.026). Compared to monolayer, spheroid resulted in a significant increase in the population with EpCAM-/CD49+ (14.6-fold, p = 0.006) and EpCAM low/-/CD44+/CD24- phenotypes (4.16-fold, p = 0.022) and ALDH high activity (9.66-fold, p = 0.037). ALDH1A and EMT-related genes were upregulated. In RNA-sequencing analysis between spheroids and monolayers, a total of 561 differentially expressed genes (2-fold change, p < 0.05) were enriched in 27 KEGG pathways including signaling pathways regulating pluripotency of stem cells. In a recurrence-free survival analysis based on the Kaplan-Meier Plotter database of the up-and down-regulated genes identified in spheroids, 15 up-, and 14 down-regulated genes were associated with poor prognosis of breast cancer patients. The media composition and spheroid culture method change in the BCSCs and EMT markers of PDBCCs, implying the importance of defining the media composition and culture method for studying PDBCCs in vitro.


  • Open Access

    Supplementary Tables and Figures from Triple-Negative Breast Cancer-Derived Extracellular Vesicles Promote a Hepatic Premetastatic Niche via a Cascade of Microenvironment Remodeling

    by Woohang Heo, Woochan Lee, Jong Ho Cheun, Eun-Shin Lee, Songbin Li, Hoe Suk Kim, Hye-Youn Son, Ju Hee Kim, Yeon Duk Woo, Doo Hyun Chung, et al.

    Supplementary Table 1. Information about patients derived xenograft models and derived patient.Supplementary Table 2. Ontology of differentially expressed genes in metastasis-harboring liver of PDX models.Supplementary Table 3. Differentially expressed genes in liver and lung of metastasis-harboring PDX models.Supplementary Table 4. Human ratio in lung and liver of additional PDX models identified by RNA sequencing.Supplementary Table 5. Gene ontology of co-expressed genes with Cx3cr1 in liver of PDX models identified by RNA sequencing.Supplementary Table 6. Top ranked genes having significant correlation with Cx3cr1 in liver of PDX models identified by RNA sequencing.Supplementary Table 7. Demographic and clinical characteristics of all patients.Supplementary Table 8. Information about used primer sequences for quantitative real-time PCRSupplementary Figure 1. Liver and lung H&E staining pictures of eight nonmetastatic PDX models a. Microscopic images of non-metastasis harboring PDX mouse model's liver (left) and lung (right) taken at 400x magnification.Supplementary Figure 2. Immunohistochemistry about CX3CR1 in liver and lung of breast cancer metastasis patients.Supplementary Figure 3. Hepatic metastasis after four weeks after orthotopic injection of 4T1 breast cancer cells identified by H&E staining.Supplementary Figure 4. Identification of pre-metastatic niche in liver tissues of 4T1 bearing mice a. mRNA expression of inflammation associated genes identified by real-time PCR in liver tissues of 4T1 bearing mice.Supplementary Figure 5. Identification of CX3CR1 positive cell population.Supplementary Figure 6. FACS analysis with anti-CX3CR1 of Raw264.7 macrophage cell lines.Supplementary Figure 7. Trans-well migration assay of BMDM with or without CX3CL1.Supplementary Figure 8. Mmp9 mRNA expression having significant correlation with Cx3cr1 mRNA expression in liver of PDX models.Supplementary Figure 9. MMP9 expression of macrophages with CX3CL1 treatment.Supplementary Figure 10. Signaling pathway of CX3CL1 treated macrophages.Supplementary Figure 11. Splenic injection of 4T1 cells inducing hepatic metastasis within two weeks in most cases.Supplementary Figure 12. mRNA expression about Cx3cr1 and Mmp9 in liver of vehicle or AZD8797 treated BALB/C mice identified by real-time PCR.Supplementary Figure 13. Correlation plot of Tnfa and Cx3cr1 mRNA expression in liver and lung of PDX models.Supplementary Figure 14. EVs isolation of CD63-mRuby-4T1.

  • Open Access

    Supplementary Tables and Figures from Triple-Negative Breast Cancer-Derived Extracellular Vesicles Promote a Hepatic Premetastatic Niche via a Cascade of Microenvironment Remodeling

    by Woohang Heo, Woochan Lee, Jong Ho Cheun, Eun-Shin Lee, Songbin Li, Hoe Suk Kim, Hye-Youn Son, Ju Hee Kim, Yeon Duk Woo, Doo Hyun Chung, et al.

    Supplementary Table 1. Information about patients derived xenograft models and derived patient.Supplementary Table 2. Ontology of differentially expressed genes in metastasis-harboring liver of PDX models.Supplementary Table 3. Differentially expressed genes in liver and lung of metastasis-harboring PDX models.Supplementary Table 4. Human ratio in lung and liver of additional PDX models identified by RNA sequencing.Supplementary Table 5. Gene ontology of co-expressed genes with Cx3cr1 in liver of PDX models identified by RNA sequencing.Supplementary Table 6. Top ranked genes having significant correlation with Cx3cr1 in liver of PDX models identified by RNA sequencing.Supplementary Table 7. Demographic and clinical characteristics of all patients.Supplementary Table 8. Information about used primer sequences for quantitative real-time PCRSupplementary Figure 1. Liver and lung H&E staining pictures of eight nonmetastatic PDX models a. Microscopic images of non-metastasis harboring PDX mouse model's liver (left) and lung (right) taken at 400x magnification.Supplementary Figure 2. Immunohistochemistry about CX3CR1 in liver and lung of breast cancer metastasis patients.Supplementary Figure 3. Hepatic metastasis after four weeks after orthotopic injection of 4T1 breast cancer cells identified by H&E staining.Supplementary Figure 4. Identification of pre-metastatic niche in liver tissues of 4T1 bearing mice a. mRNA expression of inflammation associated genes identified by real-time PCR in liver tissues of 4T1 bearing mice.Supplementary Figure 5. Identification of CX3CR1 positive cell population.Supplementary Figure 6. FACS analysis with anti-CX3CR1 of Raw264.7 macrophage cell lines.Supplementary Figure 7. Trans-well migration assay of BMDM with or without CX3CL1.Supplementary Figure 8. Mmp9 mRNA expression having significant correlation with Cx3cr1 mRNA expression in liver of PDX models.Supplementary Figure 9. MMP9 expression of macrophages with CX3CL1 treatment.Supplementary Figure 10. Signaling pathway of CX3CL1 treated macrophages.Supplementary Figure 11. Splenic injection of 4T1 cells inducing hepatic metastasis within two weeks in most cases.Supplementary Figure 12. mRNA expression about Cx3cr1 and Mmp9 in liver of vehicle or AZD8797 treated BALB/C mice identified by real-time PCR.Supplementary Figure 13. Correlation plot of Tnfa and Cx3cr1 mRNA expression in liver and lung of PDX models.Supplementary Figure 14. EVs isolation of CD63-mRuby-4T1.